title: Clinical trials for glaucoma neuroprotection are not impossible.
abstract: OBJECTIVE
  To discuss issues that affect development of new glaucoma treatments known as neuroprotection.
  
  
  RESULTS
  There are barriers to neuroprotection trials for glaucoma.
  
  
  CONCLUSIONS
  With design features discussed in the review, neuroprotection trials can be effectively carried out.
authors.affiliation: Glaucoma Services and Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. hquigley@jhmi.edu
authors.forename: Harry A
authors.initials: HA
authors.lastname: Quigley
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005901:Glaucoma / Q000517:prevention & control*; D006801:Humans; D009412:Nerve Fibers / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000517:prevention & control*; D012165:Retinal Ganglion Cells / Q000187:drug effects*
chemical_list: D018696:Neuroprotective Agents